凯莱英医药集团—成就卓越开拓新天地-棒棒糖图-数据可视化

凯莱英(002821),全称凯莱英医药集团(天津)股份有限公司(Asymchem Laboratories (Tianjin) Co., Ltd.),主营业务为提供药物研发、生产一站式CMC服务。,位于天津天津市,董事长为HAO HONG,总经理为。网址为www.asymchem.com.cn。

《凯莱英医药集团—成就卓越开拓新天地》凯莱英医药集团(Asymchem Laboratories (Tianjin) Co., Ltd.)是一家位于天津的药物研发生产企业,主要提供一站式的CMC服务。其董事长HAO HONG、总经理的全力投入使公司得以快速发展壮大。从2013年到2022年,凯莱英医药集团的营业总成本以逐年增长的的趋势不断攀升,2012年的总成本是355232900,到2022年时跃升为6620674061.97,可见公司的经营情况不断改善,注重细节,不断开拓新天地,可以谓之成就卓越。凯莱英医药集团还不断加强科技研发,吸纳新鲜血液,高素质的技术能力满足客户需求,起到了很好的支撑作用。此外,通过积极参与各种行业相关活动,凯莱英医药集团还加快了营销布局,全力拓展市场,使其市场经营步入正轨。总而言之,凯莱英医药集团已经取得了突出的成就,未来也将继续发挥此趋势,持续改善经营情况,继续开拓新天地,实现自身价值的提升,在未来的发展之路上继续成就卓越的业绩!

 凯莱英医药集团(天津)股份有限公司提供一站式CMC服务,业务涉及药物研发和生产,其营业总成本持续增长。,"002821","凯莱英","Asymchem","HAO HONG","ESG 300","国证A指","沪深300","巨潮中盘","深成指R","深市精选","深证100","深证100R","深证300","深证成指","深证新兴","中创100","中小100","中小300","中小新兴","数据可视化","上市公司财报","数据分析","棒棒糖图","花火数图","图表"

我也要免费做棒棒糖图

 凯莱英医药集团(天津)股份有限公司提供一站式CMC服务,业务涉及药物研发和生产,其营业总成本持续增长。,"002821","凯莱英","Asymchem","HAO HONG","ESG 300","国证A指","沪深300","巨潮中盘","深成指R","深市精选","深证100","深证100R","深证300","深证成指","深证新兴","中创100","中小100","中小300","中小新兴","数据可视化","上市公司财报","数据分析","棒棒糖图","花火数图","图表"

我也要免费做棒棒糖图

报表日期二、营业总成本
202212316,620,674,061.97
202112313,577,403,543.47
202012312,401,646,654.63
201912311,903,615,235.25
201812311,445,822,032.79
201712311,054,636,568.50
20161231785,982,947.01
20151231633,004,176.90
20141231593,453,919.11
20131231456,530,814.64
20121231355,232,900.00
20111231328,515,800.00

我也要免费做棒棒糖图